Every material Form 8-K NutriBand Inc. has filed with the SEC since April 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nutriband announced that its publicly traded warrants (Nasdaq: NTRBW) will expire automatically under their original terms at 5:00 p.m. Eastern Time on September 30, 2026, and will be delisted after trading ends that day. The company said the expiration has no impact on its common stock, which will continue to trade on Nasdaq as NTRB, and that unexercised warrants will become void.
Warrants (NTRBW) expire at 5:00 p.m. Eastern Time on September 30, 2026
Warrant trading ceases at market close on September 30, 2026, then warrants are removed from Nasdaq listing
Expiration requires no action from warrant holders; common stock (NTRB) is unaffected
NutriBand Inc. entered into an amended three-year, $5,000,000 credit line on June 1, 2026, replacing a $5,000,000 facility from March 19, 2023 that was scheduled to expire July 13, 2026. The line is meant to fund the FDA approval process and commercial-scale manufacturing for its AVERSA Fentanyl product, and the filing states the lender cannot convert borrowings into common stock.
Three-year, $5,000,000 credit line entered June 1, 2026, replacing the March 19, 2023 facility
Drawdowns bear interest at 7% per annum
Lender cannot convert amounts outstanding under the line into common stock
Proceeds to support FDA approval and commercial-scale manufacturing of AVERSA Fentanyl
Nutriband said in a March 30, 2026 press release that it has selected a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit the name to the FDA for approval. The filing does not report revenue, earnings, or guidance, and the company's $80 million to $200 million peak annual US sales estimate is a potential figure, not a forecast, so the news is a development step toward regulatory review.
Nutriband partnered with Brand Institute, Inc. on the brand name, and its subsidiary Drug Safety Institute will provide regulatory support on the project.
The proposed name and labeling will go to the FDA and other international regulators, and the name is being submitted to the USPTO for trademark registration.
The company says the product has the potential to reach peak annual US sales of $80 million to $200 million, citing a 2022 market analysis report.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NutriBand Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →